Yahoo
NasdaqCM - Delayed Quote USD

Chemomab Therapeutics Ltd. (CMMB)

1.1800 +0.0200 (+1.72%)
At close: 4:00:01 PM EST
Chart Range Bar
Loading chart for CMMB
  • Previous Close 1.1600
  • Open 1.2200
  • Bid 1.5900 x 100
  • Ask 1.3300 x 100
  • Day's Range 1.1500 - 1.2295
  • 52 Week Range 0.9200 - 3.0700
  • Volume 76,236
  • Avg. Volume 99,656
  • Market Cap (intraday) 9.497M
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0400
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 5.00

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

www.chemomab.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

CMMB
28.05%
MSCI WORLD (^990100-USD-STRD)
9.32%

1-Year Return

CMMB
61.44%
MSCI WORLD (^990100-USD-STRD)
0.00%

3-Year Return

CMMB
59.59%
MSCI WORLD (^990100-USD-STRD)
69.79%

5-Year Return

CMMB
97.19%
MSCI WORLD (^990100-USD-STRD)
51.56%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -2.17M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-2M
-2M
-1M
-500K
0
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
5.00 Average
1.1800 Current
5.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/27/2025
Analyst Oppenheimer
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 10 -> 25

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.27%

  • Return on Equity (ttm)

    -82.17%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.55M

  • Diluted EPS (ttm)

    -1.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.69M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -6.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: